Nick Ladin-Sienne

Nick Ladin-Sienne

Associate
Los Angeles

Email nick.ladin-sienne@​hoganlovells.com

Phone +1 310 785 4622

Fax +1 310 785 4601

Practice groupLitigation, Arbitration, and Employment

Nick Ladin-Sienne guides clients through contentious issues, whether in the form of a government subpoena or a class action complaint. As a former professional chef, Nick brings an attitude of both excellence and hospitality to his clients.

Nick investigates both domestic and international corruption. He has experience in investigations related to the False Claims Act, the Foreign Corrupt Practices Act, and money laundering. His clients include large international companies, local nonprofits, small private businesses, and large universities.

In addition to assisting clients in responding to government investigations, fighting regulatory action, and dealing with internal matters, Nick also assists clients with issues of California employment law. This dual skill set aids clients in navigating the complex interplay between internal investigations related to corruption and potential employment issues.

Nick has also successfully advocated for clients at the Supreme Court. He has assisted in filing petitions for certiorari, oppositions, and amicus briefs. During law school, Nick participated in the UCLA School of Law Supreme Court Clinic under professor Stuart Banner and externed for the Honorable Stephen R. Reinhardt on the Ninth Circuit Court of Appeals.

Education and admissions

Education

J.D., University of California, Los Angeles School of Law, 2018

B.A., Tufts University, magna cum laude with high honors, 2015

Bar admissions and qualifications

California

Court admissions

U.S. District Court, Central District of California

U.S. Court of Appeals, Ninth Circuit

Representative experience

Aided internal investigation of multinational corporation's compliance procedures relating to false claims and a related debarment action.

Advised government-sponsored research institution on California employment issues resulting from regulatory action.

Conducted due diligence of potential violation of the Foreign Corrupt Practices Act for medical device company involving clinical trials in high-risk country.

Loading data